{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:34:17Z","timestamp":1780047257189,"version":"3.53.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jcjo.2020.12.020","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T10:08:39Z","timestamp":1611742119000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incremental effect of topical and oral moxifloxacin administration with surgical intracameral prophylaxis"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7738-4688","authenticated-orcid":false,"given":"Mark K.","family":"Lukewich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Modabber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1729-619X","authenticated-orcid":false,"given":"Steve A.","family":"Arshinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2020.12.020_bib0001","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ophtha.2019.08.026","article-title":"Endophthalmitis after cataract surgery in the United States: a report from the Intelligent Research in Sight Registry, 2013-2017","volume":"127","author":"Pershing","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0002","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jcrs.2019.06.009","article-title":"The aqueous level abatement profiles of intracameral antibiotics: a comparative mathematical model of moxifloxacin, cefuroxime and vancomycin with determination of their relative efficacies","volume":"45","author":"Arshinoff","year":"2019","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0003","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcrs.2006.02.021","article-title":"for the ESCRS Endophthalmitis Study Group. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery; preliminary report of principal results from a European multicenter study","volume":"32","author":"Barry","year":"2006","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcrs.2012.10.037","article-title":"Six-year incidence of endophthalmitis after cataract surgery: Swedish national study","volume":"39","author":"Friling","year":"2013","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jcrs.2008.12.023","article-title":"Prophylactic intracameral cefazolin after cataract surgery. Endophthalmitis risk reduction and safety results in a 6-year study","volume":"35","author":"Garat","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0006","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jcrs.2005.12.135","article-title":"Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery","volume":"32","author":"Romero","year":"2006","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0007","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcrs.2009.08.023","article-title":"Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery; ten-year comparative study","volume":"36","author":"Garcia Saenz","year":"2010","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0008","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jcrs.2012.09.004","article-title":"Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa","volume":"38","author":"Van der Merwe","year":"2012","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0009","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jcrs.2012.03.024","article-title":"Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study","volume":"38","author":"Barreau","year":"2012","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0420.2005.00377.x","article-title":"Endophthalmitis following cataract surgery in Sweden: national prospective survey 1999-2001","volume":"83","author":"Wejde","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcrs.2012.07.031","article-title":"Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department","volume":"39","author":"Shorstein","year":"2013","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0012","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jcrs.2011.06.036","article-title":"Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery","volume":"37","author":"Arshinoff","year":"2011","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0013","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2015.08.023","article-title":"Endophthalmitis occurring after cataract surgery. Outcomes of more than 480,000 cataract surgeries, epidemiologic features, and risk factors","volume":"123","author":"Jabbarvand","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0014","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ophtha.2017.01.026","article-title":"Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600\u2009000 surgeries","volume":"124","author":"Haripriya","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0015","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jcrs.2019.04.018","article-title":"Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: results from 2 million consecutive cataract surgeries","volume":"45","author":"Haripriya","year":"2019","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0016","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2013.08.046","article-title":"Antibiotic choice for the prophylaxis of post-cataract extraction endophthalmitis","volume":"121","author":"Rudnisky","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0017","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.jcrs.2016.10.017","article-title":"Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis","volume":"42","author":"Arshinoff","year":"2016","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0018","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.jcrs.2016.11.008","article-title":"Antibiotic susceptibility of bacterial pathogens isolated from the aqueous and vitreous humor in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study","volume":"42","author":"Asbell","year":"2016","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0019","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcrs.2007.07.009","article-title":"Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey","volume":"33","author":"Chang","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0020","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jcrs.2015.01.014","article-title":"for the ASCRS Cataract Clinical Committee. Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2014 ASCRS member survey","volume":"41","author":"Chang","year":"2015","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0021","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.survophthal.2004.01.004","article-title":"Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones","volume":"49","author":"Hwang","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0022","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.survophthal.2005.07.001","article-title":"Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans","volume":"50","author":"Robertson","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/jop.2018.0088","article-title":"Comparative study between topical gatifloxacin 0.5% and moxifloxacin 0.5% as a prophylactic measure before intraocular surgery","volume":"35","author":"Abdel-Meguid","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0024","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20170073","article-title":"Aqueous humor concentrations of topical fluoroquinolones alone or in combination with a steroid","volume":"80","author":"Gomes","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/jop.2016.0126","article-title":"Aqueous humor penetration and biological activity of moxifloxacin 0.5% ophthalmic solution alone or with dexamethasone 0.1","volume":"33","author":"Gomes","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0026","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2147\/OPTH.S91286","article-title":"Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery","volume":"10","author":"Bucci","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0027","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/bjophthalmol-2014-306502","article-title":"Aqueous penetration of orally and topically administered moxifloxacin","volume":"99","author":"Sharma","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0028","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/0253-7613.111900","article-title":"Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery","volume":"45","author":"Halder","year":"2013","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0029","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12325-012-0016-x","article-title":"Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty","volume":"29","author":"Fukuda","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0030","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcrs.2010.12.046","article-title":"Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application","volume":"37","author":"Donnenfeld","year":"2011","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0031","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/bjo.2010.179762","article-title":"Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery","volume":"95","author":"G\u00fcng\u00f6r","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0032","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jcrs.2010.04.030","article-title":"Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients","volume":"36","author":"Yoshida","year":"2010","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0033","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jcrs.2008.04.027","article-title":"Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. part 1: aqueous concentration of moxifloxacin","volume":"34","author":"Vasavada","year":"2008","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0034","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/ICO.0b013e3181608561","article-title":"Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty","volume":"27","author":"Holland","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcrs.2006.09.015","article-title":"Aqueous humour penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery","volume":"33","author":"Ong-Tone","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2007.03.036","article-title":"Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy","volume":"144","author":"Lai","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0037","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ophtha.2006.01.061","article-title":"Fourth-generation fluoroquinolone penetration into the aqueous humor in humans","volume":"113","author":"McCulley","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0038","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/01.ico.0000157423.78275.a2","article-title":"Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor","volume":"24","author":"Katz","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0039","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ophtha.2004.09.029","article-title":"Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor","volume":"112","author":"Solomon","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0040","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.ophtha.2005.06.017","article-title":"Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients","volume":"112","author":"Kim","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archopht.123.1.39","article-title":"Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous","volume":"123","author":"Hariprasad","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0042","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/aos.12684","article-title":"Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis","volume":"93","author":"Kessel","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0043","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-3768.2011.02324.x","article-title":"Endophthalmitis following cataract surgery: the role of prophylactic postoperative chloramphenicol eye drops","volume":"91","author":"Raen","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0044","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bjophthalmol-2017-311051","article-title":"Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis","volume":"102","author":"Bowen","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jcrs.2006.10.057","article-title":"Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose","volume":"33","author":"Walter","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0046","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archopht.124.2.178","article-title":"Vitreous and aqueous penetration of orally administered moxifloxacin in humans","volume":"124","author":"Hariprasad","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0047","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/sj.eye.6702094","article-title":"Vitreous and aqueous penetration of orally administered moxifloxacin in humans","volume":"20","author":"Vedantham","year":"2006","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0048","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/bjo.2004.050054","article-title":"Penetration of moxifloxacin into the human aqueous humour after oral administration","volume":"89","author":"Kampougeris","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0049","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0886-3350(01)00997-X","article-title":"Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin","volume":"27","author":"Garc\u00eda-S\u00e1enz","year":"2001","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/43.suppl_2.83","article-title":"Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man","volume":"43","author":"Stass","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0051","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00055735-200408000-00007","article-title":"Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections","volume":"15","author":"Mah","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0052","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9394(02)01334-X","article-title":"Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics","volume":"133","author":"Mather","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0053","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/archopht.123.9.1282","article-title":"Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue [letter]","volume":"123","author":"Wagner","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0054","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1128\/AAC.31.8.1210","article-title":"Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies","volume":"31","author":"Stratton","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0055","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1185\/030079906X132668","article-title":"The effect of moxifloxacin on the normal human cornea","volume":"22","author":"Donaldson","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0056","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ajo.2005.04.015","article-title":"Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model","volume":"140","author":"Kowalski","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0057","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0002-9394(03)00294-0","article-title":"Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates","volume":"136","author":"Kowalski","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0058","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/40.5.639","article-title":"Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin","volume":"40","author":"Bauernfeind","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0059","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jcrs.2017.04.028","article-title":"Endophthalmitis prophylaxis by intracameral antibiotics: in vitro model comparing vancomycin, cefuroxime and moxifloxacin","volume":"43","author":"Libre","year":"2017","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0886-3350(01)01270-6","article-title":"Prophylactic intracameral cefuroxime: evaluation of safety and kinetics in cataract surgery","volume":"28","author":"Montan","year":"2002","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0061","series-title":"Avelox: Highlights of prescribing information","year":"2016"},{"key":"10.1016\/j.jcjo.2020.12.020_bib0062","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet Dermatol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:24:04Z","timestamp":1762104244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418221000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0008418221000053"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2020.12.020","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incremental effect of topical and oral moxifloxacin administration with surgical intracameral prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2020.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}